Five stocks that are going to get "hot" this summer part 2

Last week, we published a list of five proposed companies for the summer, with a strong potential for appreciation. We will now expand our share deals with five more companies. These companies are somewhat more aggressive investors, and on a background of May's sell-off, they are currently offering a good discount.

Adaptimmune Therapeutics

The company is in the small - caps category, and it will fit perfectly into an aggressive portfolio. The company is in the field of biotechnology on a clinical basis, focusing on the development of T-cell therapies to combat cancer. Their main technology is to refine T-cell receptors that can more easily target cancer cells and destroy them.

The company finished the first quarter with a revenue of $ 168.2 million, with management expecting this money to finance their projects by the beginning of 2020. The cost was $ 22 million over the period, down 14% from the previous year after the company successfully transferred its NY-ESO program to GlaxoSmithKine.

Citigroup rated them with a buy-in rating and a $ 8 price target.

Cloudera

The next-generation company is leading in the collection and processing of data, being called a "modern platform for machine learning and analytics". The Cloudera product is Apache Hadoop - a data ecosystem. Hadoop provides a new way of sorting and processing data, drastically reducing costs.

Nomura Instinet gives a buy-in rating to the company with a $ 14 per share price target.

Falcon Minerals

The company provides investors with a unique way to enter the energy sector. Falcon Minerals stores oil, gas and other terrestrial minerals. He also owns earth minerals and resources and receives revenue for the storage of these resources by Eagle Ford and Austin Chalk.

The company also owns other assets, such as approximately 68,000 hectares in Pennsylvania, Ohio and West Virginia, where Marcellus Shale is shale gas. Falcon Minerals announced that they already have 150 active wells around Eagle Ford, with only 28 launched already for the first quarter of 2019.

Stifel puts a buy recommendation with a $ 10 target.

Kindred Biosciences

Another small - caps biotech company with huge potential. Kindred Biosciences is a biotech company focused on preserving and improving pet life. The company's goal is to provide domestic animals with the same effective and safe drugs as humans.

The company's strategy is to identify such drugs and medications that are already approved for human use. Then develop therapeutic agents based on these drugs, applicable to dogs, cats and horses.

Stifel's Target Target is $ 14 with buy-in rating.

Zynga

This is one of the far more aggressive technology proposals that can be quite potential for the summer. Zynga is a leading company in the development of gaming and social networking games. The company has a relatively short history but has managed to develop a fairly solid portfolio of games that includes several games available through Facebook and has some of the top mobile games. The company's key franchises include FarmVile, Zynga Poker, Hit It Rich Slots and Words With Friends.

The company reported solid revenue for the first quarter, as would Wall Street expectations, with Zynga remaining an optimistic forecast for the future.

Stephens estimates shares with a buy rating and a $ 8.50 price target.

Photo: Flickr

Read more:

• Asian markets returned some of the losses but ended in the red
• European markets continue with the losing streak, safe heaven assets are rising
• Protect your portfolio with these defensive stocks
• Forex Today: 2020 kicks off with the dollar recovering amid Chinese RRR cut, trade optimism
• We look forward to a positive start to the first European session for 2020